June 22, 2026
Pancreatic cancer has a reputation. Doctors say the name and something shifts in the room. It’s usually caught late, it moves fast, and for decades, nothing doctors threw at it made much of a dent. So when I heard a new drug nearly doubled survival in a recent trial, I had to stop and actually dig into what happened.
The trial is called RASolute 302, and the drug is daraxonrasib. According to results presented at the 2026 ASCO Annual Meeting and covered by the ASCO Post in June, patients taking it lived a median of about thirteen months, compared to just seven on standard chemotherapy. Read that again. Almost double. For a cancer notorious for stealing time, that’s not a small win, that’s borrowed years handed back.
Here’s the twist: the reason pancreatic cancer has been so brutal to treat comes down to a single gene, RAS. It drives nearly every case, but it’s got this smooth, slippery shape that made it basically impossible to grab onto. Scientists tried for decades, failed for decades, and eventually just gave up and slapped a label on it: “undruggable.” It became the villain everyone knew about and nobody could touch.
Daraxonrasib walks right up to that villain and doesn’t blink. Instead of chasing one exact version of the mutation like earlier drugs tried, it blocks RAS wherever it’s active, in whatever shape it’s hiding in. It even worked in some patients whose tumors had no detectable RAS mutation at all, which is almost unheard of for a targeted drug. Oh, and it’s a pill. Not an IV, not a chair, not an afternoon plugged into a machine. Just a pill.
Researchers are already testing whether it works even better as a first move, before chemo ever enters the picture. Nobody’s calling pancreatic cancer “curable,” that would be reckless. But for the first time in a long time, people in the field are saying “transformative” and actually meaning it. When a cancer this stubborn finally cracks, even a little, that word earns its place.
Thanks for reading my blog !
MedMuse